CD274 and urinary bladder cancer: Interestingly, Bensch et al. also found increased uptake of 89Zr-Atezolizumab in the spleen and lymph nodes in response to PD-L1 blockade in bladder cancer, indicating systemic drug-induced changes in non-tumor sites caused by PD-1/PD-L1 blockade and highlighting potential utility for guiding future immunotherapy combination trials.15